PT3576740T - Tratamento de cancro - Google Patents

Tratamento de cancro

Info

Publication number
PT3576740T
PT3576740T PT187022991T PT18702299T PT3576740T PT 3576740 T PT3576740 T PT 3576740T PT 187022991 T PT187022991 T PT 187022991T PT 18702299 T PT18702299 T PT 18702299T PT 3576740 T PT3576740 T PT 3576740T
Authority
PT
Portugal
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
PT187022991T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3576740T publication Critical patent/PT3576740T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT187022991T 2017-12-20 2018-02-02 Tratamento de cancro PT3576740T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20

Publications (1)

Publication Number Publication Date
PT3576740T true PT3576740T (pt) 2023-08-18

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187022991T PT3576740T (pt) 2017-12-20 2018-02-02 Tratamento de cancro

Country Status (5)

Country Link
EA (1) EA201991818A1 (fr)
MA (1) MA47408B1 (fr)
PT (1) PT3576740T (fr)
TW (1) TWI798199B (fr)
WO (1) WO2018141921A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190826A1 (ru) * 2018-09-21 2021-06-16 Янссен Фармацевтика Нв Лечение холангиокарциномы
EP3898626A1 (fr) 2018-12-19 2021-10-27 Array Biopharma, Inc. Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr
CN113474337A (zh) * 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物
CN113423402A (zh) * 2019-02-12 2021-09-21 詹森药业有限公司 癌症治疗
CA3133348A1 (fr) * 2019-03-15 2020-09-24 Poly-Med, Inc. Systemes d'administration, methodes et compositions formant un gel in situ
EP3946340A1 (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
CN113645974A (zh) * 2019-03-29 2021-11-12 詹森药业有限公司 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
US20220233537A1 (en) * 2019-05-31 2022-07-28 Qed Therapeutics, Inc. Methods of treating urinary system cancers
CA3176713A1 (fr) 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Utilisation d'inhibiteurs de fgfr pour le traitement de sujets presentant un retard de croissance idiopathique
TWI900527B (zh) * 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
PH12022552093A1 (en) * 2020-02-12 2023-11-29 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
EP4213854A4 (fr) * 2020-09-17 2024-10-16 Ayala Pharmaceuticals Inc. Compositions comprenant des composés de bisfluoroalkyl-1,4-benzodiazépinone pour traiter un carcinome adénoïde kystique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3695B1 (ar) * 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)

Also Published As

Publication number Publication date
EA201991818A1 (ru) 2020-02-05
TWI798199B (zh) 2023-04-11
WO2018141921A1 (fr) 2018-08-09
MA47408A (fr) 2019-12-11
TW201839399A (zh) 2018-11-01
MA47408B1 (fr) 2023-08-31

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL255060A0 (en) Combined treatment for cancer
IL263123A (en) Cancer treatments
IL259996A (en) Combinations for cancer treatment
IL268463A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL274626A (en) Cancer treatment
IL247859A0 (en) Cancer treatment
ZA201707024B (en) Cancer treatment composition
IL260814A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
IL274748A (en) Improved cancer treatment
GB201522433D0 (en) Cancer treatment
GB201519734D0 (en) Cancer therapy
GB201718985D0 (en) Treatment
GB201704909D0 (en) Cancer therapy
GB201819920D0 (en) Cancer treatment
GB201711855D0 (en) Cancer therapy
GB201713852D0 (en) Cancer treatment
GB201811431D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
GB201720533D0 (en) Cancer treatments
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy